The drugs industry is an enormous multibillion businesses encompassing an immense number of companies involved in the design, production and marketing of drugs worldwide. According to the type of drugs the market can be dived into the following segments: diabetes, antifungal, antidepressant, antithrombotic, hepatitis drugs, analgesics and a far more.
Currently, the drugs market is undergoing a recovery phase in the wake of the recent decline provoked by the economic slump. The market growth is spurred by increasing demand for drugs across the globe, rising incidence of chronic as well as infectious diseases, population ageing, product innovations and constant technological advancements. North America and Europe are the most prominent regional markets. Bristol-Myers Squibb, Pharmacia, GlaxoSmithKline, Merck & Co, Novartis, Eli Lilly, Pfizer, Johnson & Johnson, Allergan, Schering-Plough, Bayer and Abbott Labs are amid global drugs arena giants.
A huge collection of the research reports covering the drugs market at different geographies can be found under this MarketPublishers’ catalogue. The researches provide comprehensive assessment of the market, characterize major market trends and disclose essential market indicators. The reports describe the competitive scenario and indicate top market players. In addition, future prospects for the drugs market are thoroughly studied in the research reports.
Publications found:
10,876
Sort by:
Global Thiamine (Vitamin B1) Market, 2021-2027
US$ 2,750.00
Thiamine, also called vitamin B1, is found in many foods including yeast, cereal grains, beans, nuts, and meat. It is widely used in foods, animal feed, and pharmaceutical preparations. According to G...
January 2021
81 pages
Global Astaxanthin Market Size study, by Source (Plant, Yeast & Microbes, Marine, Petroleum), Form (Dry, Liquid), Method of Production (Biological Process, Chemical Process), Application (Feed, Supplements, Food, Cosmetics) and Regional Forecasts 2020-2027
US$ 3,750.00
Global Astaxanthin Market is valued approximately USD 0.6 billion in 2019 and is anticipated to grow with a healthy growth rate of more than 6.90 % over the forecast period 2020-2027. Astaxanthin belo...
January 2021
200 pages
Global Human Insulin Market, By Indication (Type I Diabetes, Type II Diabetes), By Brand (Lantus, Humulin R, Novolin R, Humulin N, Exubera, Afrezza, Novolin N), By Route of Administration (Subcutaneous, Transdermal, Nasal, Intravenous, Oral and Others), By Type (Basal, Bolus, Pre-mixed, Biosimilar, Traditional), By Onset Time (Rapid Acting, Short-Acting, Intermediate Acting, Long Acting, Pre-Mixed, Inhaled, Ultra-Long Acting), By Products (Insulin Pens, Insulin Pumps, Infusion System, Injections), By Region, Forecast & Opportunities, 2025
US$ 4,500.00
Global human insulin market was valued at USD 26.91 Billion in 2019 is expected to grow at a steady CAGR of 8.01% during the forecast period. Growing geriatric population, increasing diabetic patients...
January 2021
311 pages
Antibiotics: Technologies and Global Markets
US$ 5,500.00
... through 2023 Regional dynamics of antibiotics for North America, Europe, Asia-Pacific and Other emerging markets Country specific data and analysis for ... A relevant patent analysis within the antibiotics industry Key mergers and acquisitions in the market Company profiles of the major market players in the ...
December 2020
170 pages
Vitamin B3 Market by Type (Feed Grade, Pharmaceutical Grade), Form , Source (Natural, Synthetic), Application (Pharmaceutical, Nutrition, Consumer, Agrochemicals), & Region (North America, Asia Pacific, Europe, RoW) – Global Forecast to 2025
US$ 2,970.00
The global Vitamin B3 size is estimated to be valued USD 330 million in 2020 and is expected to reach a value of USD 373 million by 2025, growing at a CAGR of 2.5% during the forecast period. Vitamin...
December 2020
151 pages
North America Vitamin D Market Size, Share & Trends Analysis Report By Source (Milk, Egg, Fruits & Vegetables, Seaweeds), By Form, By Analog, By IU Strength, By Application, And Segment Forecasts, 2020 - 2027
US$ 5,950.00
This report can be delivered to the clients within 48 Business Hours North America Vitamin D Market Growth & Trends The North America vitamin D market size is projected to reach USD 666.4 million by...
December 2020
110 pages
Global Drug-Eluting Stents Market
US$ 5,500.00
Report : This report examines the current and projected market potential of drug-eluting stents. It offers a detailed analysis of the regulatory scenario, competitive environment, pipeline, technologi...
November 2020
127 pages
Drug-Coated Balloons Market - Global Outlook and Forecast 2020-2025
US$ 3,500.00
... existing commercial drug-coated balloons. Drug-Coated Balloons Market – Segmentation This market research report includes a detailed segmentation of the market by indication, end-users, and geography.The global drug-coated balloons market by indication ...
November 2020
263 pages
Vitamin China E-News 2010 (12 issues per year)
US$ 2,916.00
... entire vitamin industry chain, from raw materials to end consumption. It includes breaking news from China and abroad, the latest market data (price, ... possible reduction in sodium bichromate supply may also stimulate the price of vitamin K3. China has recently increased its efforts on the healthcare food market ...
November 2020
30 pages
Global HIV Drugs Market By Medication Class (Multi-class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Entry Inhibitors, and HIV Integrase Strand Transfer Inhibitors): Opportunity Analysis and Industry Forecast, 2020–2027
US$ 5,243.00
The global HIV drugs market was valued at $30,891.48 million in 2019, and is expected to reach $36,495.47 million by 2027, registering a CAGR of 3.8% from 2020 to 2027. Human immunodeficiency virus (H...
November 2020
237 pages
Amyloidosis R&D Pipeline Analysis Report, Q4 2020
US$ 1,529.00
Amyloidosis Pipeline Overview The Q4 Amyloidosis pipeline report is part of the VPA Metabolic Disorder disease pipeline service. This quarterly review describes the pipeline of drugs under development...
October 2020
151 pages
Anaphylaxis R&D Pipeline Analysis Report, Q4 2020
US$ 1,529.00
Anaphylaxis Pipeline Overview The Q4 Anaphylaxis pipeline report is part of the VPA immunology disease pipeline service. This quarterly review describes the pipeline of drugs under development for Ana...
October 2020
52 pages
Anthrax R&D Pipeline Analysis Report, Q4 2020
US$ 1,529.00
Anthrax Pipeline Overview The Q4 Anthrax pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Anthrax...
October 2020
116 pages
Aspergillosis R&D Pipeline Analysis Report, Q4 2020
US$ 1,529.00
Aspergillosis Pipeline Overview The Q4 Aspergillosis pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development...
October 2020
135 pages
Bacterial Vaginosis R&D Pipeline Analysis Report, Q4 2020
US$ 1,529.00
Bacterial Vaginosis Pipeline Overview The Q4 Bacterial Vaginosis pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under...
October 2020
76 pages
Birch Pollen Allergy R&D Pipeline Analysis Report, Q4 2020
US$ 1,529.00
Birch Pollen Allergy Pipeline Overview The Q4 Birch Pollen Allergy pipeline report is part of the VPA immunology disease pipeline service. This quarterly review describes the pipeline of drugs under d...
October 2020
41 pages
Botulism R&D Pipeline Analysis Report, Q4 2020
US$ 1,529.00
Botulism Pipeline Overview The Q4 Botulism pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Botul...
October 2020
41 pages
Candidiasis R&D Pipeline Analysis Report, Q4 2020
US$ 1,979.00
Candidiasis Pipeline Overview The Q4 Candidiasis pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for...
October 2020
210 pages
Cat Allergy R&D Pipeline Analysis Report, Q4 2020
US$ 1,529.00
Cat Allergy Pipeline Overview The Q4 Cat Allergy pipeline report is part of the VPA immunology disease pipeline service. This quarterly review describes the pipeline of drugs under development for Cat...
October 2020
42 pages
Chikungunya Fever R&D Pipeline Analysis Report, Q4 2020
US$ 1,979.00
Chikungunya Fever Pipeline Overview The Q4 Chikungunya Fever pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under dev...
October 2020
138 pages
Chlamydia Infections R&D Pipeline Analysis Report, Q4 2020
US$ 1,529.00
Chlamydia Infections Pipeline Overview The Q4 Chlamydia Infections pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs und...
October 2020
72 pages
Cholera R&D Pipeline Analysis Report, Q4 2020
US$ 1,529.00
Cholera Pipeline Overview The Q4 Cholera pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Cholera...
October 2020
51 pages
Coccidioidomycosis R&D Pipeline Analysis Report, Q4 2020
US$ 1,529.00
Coccidioidomycosis Pipeline Overview The Q4 Coccidioidomycosis pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under d...
October 2020
51 pages
Cryptococcosis R&D Pipeline Analysis Report, Q4 2020
US$ 1,529.00
Cryptococcosis Pipeline Overview The Q4 Cryptococcosis pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under developme...
October 2020
62 pages
Cryptosporidiosis R&D Pipeline Analysis Report, Q4 2020
US$ 1,529.00
Cryptosporidiosis Pipeline Overview The Q4 Cryptosporidiosis pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under dev...
October 2020
35 pages
Dengue Fever R&D Pipeline Analysis Report, Q4 2020
US$ 1,979.00
Dengue Fever Pipeline Overview The Q4 Dengue Fever pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development f...
October 2020
163 pages
Diabetic Neuropathy R&D Pipeline Analysis Report, Q4 2020
US$ 1,529.00
Diabetic Neuropathy Pipeline Overview The Q4 Diabetic Neuropathy pipeline report is part of the VPA Metabolic Disorder disease pipeline service. This quarterly review describes the pipeline of drugs u...
October 2020
142 pages
Diphtheria R&D Pipeline Analysis Report, Q4 2020
US$ 1,529.00
Diphtheria Pipeline Overview The Q4 Diphtheria pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for D...
October 2020
92 pages
Genital Herpes R&D Pipeline Analysis Report, Q4 2020
US$ 1,529.00
Genital Herpes Pipeline Overview The Q4 Genital Herpes pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under developme...
October 2020
128 pages
Gonorrhea R&D Pipeline Analysis Report, Q4 2020
US$ 1,529.00
Gonorrhea Pipeline Overview The Q4 Gonorrhea pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Gon...
October 2020
94 pages
